RevoNA Bio is a female-founded University of Portsmouth spin-out working on RNA-targeted drug discovery. Its patented high-throughput RNA biology platform generates RNA structure/function datasets that feed a machine-learning prediction engine, supporting hit identification, optimisation and safety assessment for RNA-targeted small molecules with applications across human, animal and plant health. Founded in 2022 and led by co-founders Charlotte Henderson (CEO) and Anastasia Callaghan (CSO), the UK company raised around £2.1m during 2026.
1
Round
1
Industry
4
Tags
Sep 11, 2026
Latest raise
Funding activity · 1 round
Sep 11, 2026
GBP 250,000
Seed
Revona Bio Adds £250K in Seed Funding Revona Bio, a female founded spin out from the University of Portsmouth, has raised £250,000 in seed funding. The round i…
Read articlePricing
Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.
For individuals and small teams getting started with AI buyer intelligence.
$149
/month
Features
For outbound teams and agencies that need more coverage and faster signal cadence.
$249
/month
Features
Act on this raise
Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.
